Abstract
Background: Diabetic nephropathy (DN) is the most common cause of end-stage renal failure. Grape seed proanthocyanidin extracts (GSPE) are powerful antioxidants. However, the role of GSPE on advanced glycation end products (AGEs), receptor for advanced glycation end products (RAGE) and expression of connective tissue growth factor (CTGF) in DN has not been elucidated. Using streptozotocin-induced diabetic rats, we evaluated the effects of GSPE in DN. Methods: Wistar rats were induced into diabetes using streptozotocin injections and diabetic rats were treated with GSPE (dosage: 500 mg·kg–1·day–1) for 24 weeks. The renal pathological changes were examined with PAS staining and electron microscope. The mRNA and protein expression of RAGE and CTGF in kidney were detected by RT-PCR, Western blot and immunohistochemical staining. Results: Treated animals showed reduction in serum AGEs (p < 0.01), proteinuria (p < 0.01) and systolic blood pressure (p < 0.01). GSPE reduced the expression of RAGE (p < 0.01) and CTGF (p < 0.01) in the kidney, which were contributing to reversal of extracellular matrix accumulation in DN. Conclusion: Our results suggest that GSPE hold substantial promise for the treatment of DN. GSPE can decrease proteinuria, attenuating the progression of nephropathy in diabetic rats. Renoprotective effects of GSPE are correlated with suppression on AGEs/RAGE axis, downregulating expression of CTGF.
References
1.
Ziyadeh FN, Sharma K: Overview: combating diabetic nephropathy. J Am Soc Nephrol 2003;14:1355–1357.
[PubMed]
2.
Suzuki D, Toyoda M, Yamamoto N, Miyauchi M, Katoh M, Kimura M, Maruyama M, Honma M, Umezono T, Yagame M: Relationship between the expression of advanced glycation end products (AGE) and the receptor for AGE (RAGE) mRNA in diabetic nephropathy. Intern Med 2006;45:435–441.
[PubMed]
3.
Coughlan MT, Cooper ME, Forbes JM: Renal microvascular injury in diabetes: RAGE and redox signaling. Antioxid Redox Signal 2007;9:331–342.
[PubMed]
4.
Wendt TM, Tanji N, Guo J, et al: RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123–1137.
[PubMed]
5.
Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H: The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-α through nuclear factor-κB, and by 17β-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 2000;275:25781–25790.
[PubMed]
6.
Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H: Roles of the receptor for advanced glycation end products in diabetes-induced vascular injury. J Pharmacol Sci 2005;97:305–311.
[PubMed]
7.
Umezono T, Toyoda M, Kato M, Miyauchi M, Kimura M, Maruyama M, Honma M, Yagame M, Suzuki D: Glomerular expression of CTGF, TGF-β1 and type IV collagen in diabetic nephropathy. J Nephrol 2006;19:751–757.
[PubMed]
8.
Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ, Goldschmeding R: Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998;53:853–861.
[PubMed]
9.
Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM: Glomerular expression of thrombospondin-1, transforming growth factor-β and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 2005;48:2650–2660.
[PubMed]
10.
Kobayashi T, Inoue T, Okada H, Kikuta T, Kanno Y, Nishida T, Takigawa M, Sugaya T, Suzuki H: Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-β produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol 2005;9:114–121.
[PubMed]
11.
Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006;17:2484–2494.
[PubMed]
12.
Ariga T: Theantioxidative function, preventive action on disease and utilization of proanthocyanidins. Biofactors 2004;21:197–201.
[PubMed]
13.
Nakagawa T, Yokozawa T, Satoh A, Kim HY: Attenuation of renal ischemia-reperfusion injury by proanthocyanidin-rich extract from grape seeds. J Nutr Sci Vitaminol (Tokyo) 2005;51:283–286.
[PubMed]
14.
Liu YN, Shen XN, Yao GY: Effects of grape seed proanthocyanidin extracts on experimental diabetic nephropathy in rats. Wei Sheng Yan Jiu 2006;35:703–705.
[PubMed]
15.
Zhou Y, Ma Y, Gao H, Cheng M, You B: Effects of grape seed proanthocyanidin extracts on nonenzymatic glycation end products in diabetic rats. Chin J Geriatr 2005,24:49–52
16.
Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem1992;267:5133–5138.
[PubMed]
17.
Song Y, Li C, Cai L: Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. Exp Mol Pathol 2004;76:66–75.
[PubMed]
18.
Lane PH, Steffes MW, Mauer SM: Estimation of glomerular volume: a comparison of four methods. Kidney Int 1992;141:1085–1089.
19.
Solez K, Axelsen RA, Benediktsson H, Burdick JF, Cohen AH, Colvin RB, Croker BP, Droz D, Dunnill MS, Halloran PF, et al: International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff Working Classification of Kidney Transplant Pathology. Kidney Int 1993;44:411–422.
[PubMed]
20.
Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestilä M, Koskimies O, Jalanko H: Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol 2004;15:2611–2618.
[PubMed]
21.
Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR: Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999;274:5830–5834.
[PubMed]
22.
Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K: Animal model of sclerotic skin. I. Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456–462.
[PubMed]
23.
Lam S, van der Geest RN, Verhagen NA, van Nieuwenhoven FA, Blom IE, Aten J, Goldschmeding R, Daha MR, van Kooten C: Connective tissue growth factor and IGF-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 2003;52:2975–2983.
[PubMed]
24.
Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261–268.
[PubMed]
25.
Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 2005;18:1385–1396.
[PubMed]
26.
Schena FP, Gesualdo L: Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005;16(suppl 1):S30–S33.
[PubMed]
27.
Tan AL, Forbes JM, Cooper ME: AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 2007;27:130–143.
[PubMed]
28.
Zhou G, Li C, Cai L: Advanced glycation end products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor-β-independent pathway. Am J Pathol 2004;165:2033–2043.
[PubMed]
29.
Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H: Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261–268.
[PubMed]
30.
Myint KM, Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H: RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low-molecular-weight heparin. Diabetes 2006;55:2510–2522.
[PubMed]
31.
Giardino I, Edelstein D, Brownlee M: Bcl-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996;97:1422–1428.
[PubMed]
32.
Sajithlal G B, Chithra P, Chandrakasan G: The role of metal-catalyzed oxidation in the formation of advanced glycation end products: an in vitro study on collagen. Free Radic Biol Med 1998;25:265–269.
[PubMed]
33.
Preuss HG, Montamarry S, Echard B, Scheckenbach R, Bagchi D, Montamarry S, Echard B, et al: Long-term effects of chromium, grape seed extract, and zinc on various metabolic parameters of rats. Mol Cell Biochem 2001;223:95–102.
[PubMed]
34.
Tomohiro T, Kumai T, Sato T, Takeba Y, Kobayashi S, Kimura K: Hypertension aggravates glomerular dysfunction with oxidative stress in a rat model of diabetic nephropathy. Life Sci 2007;80:1364–1372.
[PubMed]
35.
Thomas MC, Atkins RC: Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 2006;66:2213–2234.
[PubMed]
36.
Guha M, Xu ZG, Tung D, Lanting L, Natarajan R: Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007;21:3355–3368.
[PubMed]
37.
Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004;15:1430–1440.
[PubMed]
38.
Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 2003;17:1762–1764.
[PubMed]
39.
Pinent M, Blay M, Blade MC, et al: Grape seed-derived procyanidins have an antihyperglycemic effect in streptozotocin-induced diabetic rats and insulinomimetic activity in insulin-sensitive cell lines. Endo- crinology 2004;145:4985–4990.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
